Orris

Tell be best practical way to decrease weight as per physian choice as per doctor recommendation, ayurvedic, as well as research paper ,diffrent journals , diffrent supplements as well as , ayurvedic as well as allopathic formula in point wise from best standard source people opinion I just want to decrease weight drastically.

Reading File
Now let me run parallel searches across medical library, PubMed, and web to get the most comprehensive, evidence-based answer.
Finding Sources
Searching PubMed

"obesity"[MeSH Terms] AND "weight loss"[MeSH Terms] AND "treatment"[MeSH Terms]

Searching the Web

best evidence-based weight loss methods 2025 physician recommended ayurvedic supplements allopathic

Finding Sources
Searching PubMed

"weight loss" AND "GLP-1" AND "semaglutide"

Reading Web Page

https://www.goodrx.com/conditions/weight-loss/best-pills

Finding Sources
Searching PubMed

"intermittent fasting" OR "caloric restriction" AND "weight loss" AND "obesity"

I now have strong research data. Let me compile the comprehensive answer.

Complete Weight Loss Guide: Physician-Recommended, Ayurvedic & Research-Backed

Important disclaimer: "Drastic" rapid weight loss (more than 1-2 lbs/week) carries real medical risks - gallstones, muscle loss, nutrient deficiency, and cardiac strain. The most effective strategies below create fast initial results while remaining safe. Always consult your doctor before starting any program, especially medications.

PART 1 - PHYSICIAN / ALLOPATHIC APPROACH

A. Dietary Foundation (Non-Negotiable)

  1. Caloric Deficit - Create a 500-1000 kcal/day deficit to lose 0.5-1 kg/week. This is the single most evidence-based step.
  2. Protein-First Diet - Aim for 1.2-1.6 g/kg body weight/day. High protein preserves muscle mass during fat loss and reduces hunger.
  3. Low-Glycemic Index Foods - Whole grains, legumes, non-starchy vegetables. Reduces insulin spikes that drive fat storage.
  4. Eliminate Ultra-Processed Foods - Remove refined sugar, sugary drinks, packaged snacks, and fried foods immediately.
  5. Portion Control + Food Journaling - Tracking food intake consistently leads to significantly more weight lost.

B. Intermittent Fasting (Strong Evidence)

  • 16:8 method - Eat within an 8-hour window, fast 16 hours. Most popular and sustainable.
  • 5:2 method - Eat normally 5 days, restrict to 500 kcal on 2 non-consecutive days.
  • A 2025 Cochrane systematic review (PMID: 41692034) and a 2025 BMJ network meta-analysis (PMID: 40533200) both confirm intermittent fasting produces clinically meaningful weight loss comparable to continuous caloric restriction, with additional metabolic benefits.

C. Exercise Protocol

  1. Resistance Training 3x/week - Builds muscle, raises basal metabolic rate (BMR). Most underused weight loss tool.
  2. Cardio 150-300 min/week - Brisk walking, cycling, swimming. Zone 2 cardio (able to hold a conversation) burns fat efficiently.
  3. HIIT 2x/week - 20-minute sessions with sprint/rest intervals. Burns more calories post-workout due to afterburn (EPOC effect).
  4. Daily Steps Goal - 8,000-10,000 steps/day is independently associated with weight reduction and lower mortality.

D. Prescription Medications (Doctor-Prescribed Only)

These are the most powerful medical tools currently available:
  1. Semaglutide (Wegovy / Ozempic) - GLP-1 receptor agonist. Leads to 15-20% body weight loss. Now available as oral pill (FDA approved 2025). A 2025 systematic review in Annals of Internal Medicine (PMID: 39761578) confirms efficacy in non-diabetics. A network meta-analysis in Metabolism (2024) (PMID: 39305981) shows tirzepatide and semaglutide are the top performers among GLP-1 agents.
  2. Tirzepatide (Mounjaro/Zepbound) - Dual GIP/GLP-1 agonist. Up to 22-25% body weight reduction in trials - the most effective medication currently available.
  3. Orlistat (Xenical / Alli) - Blocks fat absorption (30% of dietary fat). OTC available. Less dramatic but adds ~3-5 kg extra loss vs. diet alone.
  4. Phentermine/Topiramate (Qsymia) - Appetite suppressant + anticonvulsant combination. Effective short-to-medium term.
  5. Naltrexone/Bupropion (Contrave) - Targets reward/craving centers in the brain. Reduces emotional eating.
  6. Metformin - Not FDA-approved for weight loss but widely used off-label; reduces appetite, improves insulin sensitivity, modest weight effect (~2-3 kg).

E. Non-Surgical Procedures

  1. Endoscopic Sleeve Gastroplasty (ESG) - Reduces stomach volume by ~70% using sutures through endoscope. No incision.
  2. Intragastric Balloon - Temporary balloon placed in stomach for 6 months to create early fullness.
  3. Bariatric Surgery (for BMI >35-40) - Sleeve gastrectomy or Roux-en-Y gastric bypass produces 30-40% excess body weight loss, the most drastic option.

PART 2 - AYURVEDIC APPROACH

Ayurveda attributes excess weight to imbalanced Kapha dosha and impaired Agni (digestive fire), with accumulation of Ama (undigested toxins).

Ayurvedic Herbs & Formulations

  1. Triphala (Amalaki + Haritaki + Bibhitaki) - Cleanses the gut, regulates bowel movements, reduces BMI and waist circumference. Take 1 tsp powder with warm water at bedtime.
  2. Guggul (Commiphora mukul) - Guggulsterones reduce cholesterol and stimulate fat breakdown. Especially effective for metabolic/lipid-related weight gain.
  3. Medohar Guggulu - Classical Ayurvedic formulation literally meaning "destroyer of fat." Targets Meda Dhatu (fat tissue), improves digestion, eliminates toxins.
  4. Trikatu (Black pepper + Long pepper + Dry ginger) - Rekindles digestive fire (Agni), removes metabolic waste, boosts fat metabolism.
  5. Garcinia Cambogia (Vrikshamla) - Contains hydroxycitric acid (HCA); reduces appetite and inhibits fat synthesis.
  6. Ashwagandha - Reduces cortisol (stress hormone), which directly drives abdominal fat storage. Improves thyroid function.
  7. Kanchanar Guggulu - Specifically for thyroid-related or glandular weight gain.
  8. Punarnava (Boerhavia diffusa) - Diuretic and anti-inflammatory. Helps remove water retention and supports kidney function.
  9. Vijayasar (Pterocarpus marsupium) - Reduces blood sugar and fat accumulation; used in diabetic-type obesity.

Ayurvedic Lifestyle Practices

  1. Eat largest meal at lunch (11 AM-1 PM) - Agni is strongest mid-day per Ayurvedic principles.
  2. Drink warm water/herbal teas throughout the day - facilitates Ama removal.
  3. Udwarthanam - Dry herbal powder massage. Breaks down fat deposits, tones body, improves circulation.
  4. Panchakarma detox (supervised by a vaidya) - Deep cleansing protocol to reset metabolism.
  5. Yoga - Surya Namaskar (12 rounds daily), Bhujangasana, Dhanurasana, Kapalbhati pranayama (boosts metabolism).

PART 3 - EVIDENCE-BASED SUPPLEMENTS (Research-Backed)

  1. Berberine - Found in barberry/goldenseal. Acts similarly to Metformin on insulin pathways. A review in the International Journal of Obesity showed significant drops in BMI vs. placebo. Dose: 500 mg 3x/day with meals.
  2. Probiotics/Synbiotics - A 2025 review in Scientific Reports found probiotic supplementation significantly reduced body weight, waist circumference, and body fat in overweight people.
  3. Green Tea Extract (EGCG) - Boosts thermogenesis and fat oxidation. 400-500 mg/day standardized extract.
  4. Fiber Supplements (Psyllium, Glucomannan) - Glucomannan (konjac fiber) expands in stomach to create fullness; reduces calorie intake. Take before meals with large glass of water.
  5. Conjugated Linoleic Acid (CLA) - Reduces body fat mass modestly; useful for body recomposition.
  6. 5-HTP (Hydroxytryptophan) - Precursor to serotonin; reduces appetite and sugar cravings. 100-200 mg before meals.
  7. Chromium Picolinate - Reduces carbohydrate cravings; improves insulin sensitivity. 200-400 mcg/day.
  8. Vitamin D3 + K2 - Vitamin D deficiency is linked to obesity. Supplementing helps insulin function and weight regulation.

PART 4 - BEHAVIORAL & LIFESTYLE STRATEGIES (Often Overlooked)

  1. Sleep 7-9 hours/night - Poor sleep raises ghrelin (hunger hormone) and lowers leptin (satiety hormone). Single biggest overlooked driver of weight gain.
  2. Stress Management - Chronic cortisol drives belly fat. Meditation, deep breathing, and nature walks are as important as diet.
  3. Social Accountability - Joining a structured program (e.g., WeightWatchers, Noom, dietitian-led programs) doubles success rates vs. going alone.
  4. Time-Restricted Activity - Exercise before breakfast (fasted state) burns more fat per session.
  5. Hydration - 500 ml water 30 minutes before meals reduces calorie intake by ~13% per meal.

PRIORITIZED ACTION PLAN (Ranked by Impact)

PriorityActionExpected Impact
1GLP-1 medication (if prescribed)15-25% body weight
2Caloric deficit + high-protein diet5-15% body weight
3Resistance training + daily walking3-8% body weight
4Intermittent fasting (16:8)3-8% body weight
5Berberine / Metformin off-label2-5% body weight
6Triphala + Guggul (Ayurvedic)1-4% body weight
7Sleep optimization + stress control2-5% body weight
8Probiotics + fiber supplements1-3% body weight

Key Research References

  • Semaglutide systematic review - PMID 39761578 - Annals of Internal Medicine (2025)
  • GLP-1 network meta-analysis - PMID 39305981 - Metabolism (2024)
  • Emerging pharmacotherapies - PMID 39952695 - Pharmacological Reviews (2025)
  • Intermittent fasting Cochrane review - PMID 41692034 - Cochrane Database (2026)
  • Intermittent fasting BMJ network meta-analysis - PMID 40533200 - BMJ (2025)
Bottom line: For the fastest safe weight loss, combine a GLP-1 medication (consult your doctor) + caloric deficit with high protein + resistance training + 16:8 intermittent fasting. Add Triphala, Berberine, and Guggul as complementary support. Fix sleep and stress - these alone can stall or drive weight gain despite perfect diet. There is no single magic bullet - the combination approach produces the most dramatic and sustained results.

Headache give me standard knowledge about this topic from international headache society as well as journal ,research article best source

Reading File
Searching sources... Running parallel searches across the medical textbook library, PubMed, IHS guidelines, and web sources simultaneously.
Finding Sources
Searching PubMed

"headache" AND "International Headache Society" AND "classification"

Searching the Web

International Headache Society ICHD-3 headache classification 2024 2025 guidelines

Finding Sources
Searching PubMed

"migraine" AND "CGRP" AND "treatment guidelines"

Reading Web Page

https://ichd-3.org

Finding Sources
Searching PubMed

"migraine" AND "CGRP monoclonal antibody" AND "prevention"

Reading Article

PMID: 38166472

Reading File
Searching PubMed

"migraine" AND "acute treatment" AND "triptans OR gepants OR ditans"

Reading File
Reading Article

PMID: 40277321

Reading Article

PMID: 39293828

Reading Article

PMID: 41722594

Searching Images

headache classification types migraine tension cluster diagram ICHD

Abbreviations: ICHD-3: International Classification of Headache Disorders, 3rd edition <table><thead><tr><th colspan="5">Sidebar 3: Common Primary Headache Disorders Criteria<sup>†</sup></th></tr><tr><th></th><th></th><th>Tension-Type Headache<sup>a</sup></th><th>Migraine Headache<sup>b</sup></th><th>Cluster Headache<sup>c</sup></th></tr></thead><tbody><tr><td rowspan="2">Headache Duration and Frequency</td><td>Duration</td><td>30 minutes to 7 days</td><td>4–72 hours</td><td>15–180 minutes</td></tr><tr><td>Frequency</td><td>Variable</td><td>Variable</td><td>Once every other day to eight per day; often occurring at the same time of day</td></tr><tr><td rowspan="3">Headache Characteristics</td><td>Severity</td><td>Mild to moderate</td><td>Moderate to severe</td><td>Severe or very severe</td></tr><tr><td>Location</td><td>Bilateral</td><td>Unilateral</td><td>Unilateral orbital, supraorbital, or temporal pain or any combination of such pain</td></tr><tr><td>Quality</td><td>Pressing or tightening, non-pulsating</td><td>Throbbing or pulsating</td><td>Stabbing, boring</td></tr><tr><td></td><td>Aggravated by routine physical activity</td><td>Not aggravated by routine activity</td><td>Aggravated by routine activity</td><td>Causes a sense of agitation or restlessness; routine activity might improve symptoms</td></tr></tbody></table>

Abbreviations: ICHD-3: International Classification of Headache Disorders, 3rd edition <table><thead><tr><th colspan="5">Sidebar 3: Common Primary Headache Disorders Criteria<sup>†</sup></th></tr><tr><th></th><th></th><th>Tension-Type Headache<sup>a</sup></th><th>Migraine Headache<sup>b</sup></th><th>Cluster Headache<sup>c</sup></th></tr></thead><tbody><tr><td rowspan="2">Headache Duration and Frequency</td><td>Duration</td><td>30 minutes to 7 days</td><td>4–72 hours</td><td>15–180 minutes</td></tr><tr><td>Frequency</td><td>Variable</td><td>Variable</td><td>Once every other day to eight per day; often occurring at the same time of day</td></tr><tr><td rowspan="3">Headache Characteristics</td><td>Severity</td><td>Mild to moderate</td><td>Moderate to severe</td><td>Severe or very severe</td></tr><tr><td>Location</td><td>Bilateral</td><td>Unilateral</td><td>Unilateral orbital, supraorbital, or temporal pain or any combination of such pain</td></tr><tr><td>Quality</td><td>Pressing or tightening, non-pulsating</td><td>Throbbing or pulsating</td><td>Stabbing, boring</td></tr><tr><td></td><td>Aggravated by routine physical activity</td><td>Not aggravated by routine activity</td><td>Aggravated by routine activity</td><td>Causes a sense of agitation or restlessness; routine activity might improve symptoms</td></tr></tbody></table>

This composite educational graphic consists of a side-by-side comparison between a clinical bar chart and neuroimaging statistical maps. On the left, a grouped bar graph illustrates the distribution of headache types—Tension-Type Headache (TTH), Migraine (MiG), and No Headache (None)—in cancer patients categorized by their pathological complete response (pCR) to neoadjuvant chemotherapy (NAC). The pCR group shows a predominance of Migraine (57%), while the non-pCR group shows a higher prevalence of TTH (48%). On the right, a statistical map overlay on a T1-weighted MRI template displays regions of altered brain metabolism in sagittal, coronal, and axial views. Yellow-red clusters indicate a positive test statistic (intensity scale 0 to 4) localized predominantly in the bilateral anterior medial frontal cortex. The visual highlights a specific neuro-oncological correlation between chemotherapy response clinical outcomes and functional brain imaging biomarkers, specifically targeting metabolic variations in patients suffering from different primary headache disorders.

This composite educational graphic consists of a side-by-side comparison between a clinical bar chart and neuroimaging statistical maps. On the left, a grouped bar graph illustrates the distribution of headache types—Tension-Type Headache (TTH), Migraine (MiG), and No Headache (None)—in cancer patients categorized by their pathological complete response (pCR) to neoadjuvant chemotherapy (NAC). The pCR group shows a predominance of Migraine (57%), while the non-pCR group shows a higher prevalence of TTH (48%). On the right, a statistical map overlay on a T1-weighted MRI template displays regions of altered brain metabolism in sagittal, coronal, and axial views. Yellow-red clusters indicate a positive test statistic (intensity scale 0 to 4) localized predominantly in the bilateral anterior medial frontal cortex. The visual highlights a specific neuro-oncological correlation between chemotherapy response clinical outcomes and functional brain imaging biomarkers, specifically targeting metabolic variations in patients suffering from different primary headache disorders.

An anatomical diagram illustrating two schematic views of the human brain—a medial sagittal section (left) and a coronal section (right)—mapping the neuroanatomical targets for headache treatments. The illustration utilizes a color-coded system to link specific brain regions to their clinical relevance in migraine, cluster headache, and medication overuse headache management. Key areas identified in the sagittal view include the prefrontal cortex, somatosensory cortex, cuneus/precuneus, occipital cortex, hypothalamus, periaqueductal gray (PAG), spinal trigeminal nucleus, and cerebellum. The coronal view highlights the cingulate gyrus, thalamus, insula, temporal cortex, hippocampus, and amygdala. Each region is associated with specific therapeutic modalities mentioned in clinical literature, such as NSAIDs, monoclonal antibodies (Erenumab, Galcanezumab), onabotulinum toxin A, neuromodulation, and deep brain stimulation. This infographic serves as a pedagogical summary of the central nervous system structures involved in headache pathophysiology and the spatial distribution of pharmacological and interventional treatment targets.

An anatomical diagram illustrating two schematic views of the human brain—a medial sagittal section (left) and a coronal section (right)—mapping the neuroanatomical targets for headache treatments. The illustration utilizes a color-coded system to link specific brain regions to their clinical relevance in migraine, cluster headache, and medication overuse headache management. Key areas identified in the sagittal view include the prefrontal cortex, somatosensory cortex, cuneus/precuneus, occipital cortex, hypothalamus, periaqueductal gray (PAG), spinal trigeminal nucleus, and cerebellum. The coronal view highlights the cingulate gyrus, thalamus, insula, temporal cortex, hippocampus, and amygdala. Each region is associated with specific therapeutic modalities mentioned in clinical literature, such as NSAIDs, monoclonal antibodies (Erenumab, Galcanezumab), onabotulinum toxin A, neuromodulation, and deep brain stimulation. This infographic serves as a pedagogical summary of the central nervous system structures involved in headache pathophysiology and the spatial distribution of pharmacological and interventional treatment targets.

I now have comprehensive data from all major sources. Let me compile the full, authoritative answer.

Headache: Standard International Knowledge

Sources: ICHD-3 (IHS), Medical Textbooks, PubMed Journals

PART 1 - WHAT IS HEADACHE? (IHS DEFINITION)

Headache is one of the most common neurological symptoms worldwide. The pain arises not from the brain parenchyma (which has no pain receptors), but from mechanical traction, inflammation, or irritation of innervated structures: blood vessels, meninges, scalp, and skull. The supratentorial dura is innervated by the trigeminal nerve (CN V); the posterior fossa dura by CN IX, X, and cervical nerves 1-3.
  • Neuroanatomy through Clinical Cases, 3rd Ed.

PART 2 - ICHD-3 CLASSIFICATION (International Headache Society)

The International Classification of Headache Disorders, 3rd Edition (ICHD-3), published in Cephalalgia (2018), is the globally accepted standard. ICHD-4 is currently in active development (workshops held September 2025, led by Chair Prof. Peter J. Goadsby). A 2024 review in Cephalalgia (PMID: 38166472) by original ICHD chairman Jes Olesen traces its history and ongoing evolution.

The Two Master Categories

CategoryDefinition
Primary HeadacheHeadache IS the disorder - no underlying structural cause
Secondary HeadacheHeadache is a symptom of another underlying disorder

PART 3 - PRIMARY HEADACHES (ICHD-3 Part 1-4)

A. MIGRAINE (ICHD-3 Code: 1)

The most common primary headache, affecting ~15% of the global population with a 2.1:1 female-to-male ratio.
Common Primary Headache Disorders Criteria - ICHD-3

ICHD-3 Diagnostic Criteria for Migraine Without Aura (1.1):

  1. At least 5 attacks lasting 4-72 hours
  2. At least 2 of the following: Unilateral location / Pulsating quality / Moderate-severe intensity / Aggravated by routine activity
  3. At least 1 of: Nausea/vomiting OR Photophobia + phonophobia
  4. Not better accounted for by another ICHD-3 diagnosis

ICHD-3 Subtypes:

  • 1.1 - Migraine without aura
  • 1.2 - Migraine with aura (visual, sensory, speech, motor, brainstem, retinal)
  • 1.3 - Chronic migraine (≥15 headache days/month for >3 months, ≥8 meeting migraine criteria)
  • 1.4 - Status migrainosus (>72 hours, debilitating)
  • 1.5 - Persistent aura without infarction
  • 1.6 - Migrainous infarction

Pathophysiology:

  • Cortical spreading depression (CSD) - wave of spreading depolarization causing aura
  • Trigeminovascular activation - CGRP (calcitonin gene-related peptide) released from trigeminal nerve terminals causes neurogenic inflammation
  • Central sensitization - explains allodynia and cutaneous hypersensitivity
  • Genetic basis: ~75% of patients have a positive family history
  • Triggers: stress, hormonal changes (menstrual cycle), sleep disruption, certain foods (tyramine, alcohol, caffeine withdrawal), sensory stimuli

B. TENSION-TYPE HEADACHE (ICHD-3 Code: 2)

The most prevalent headache disorder worldwide (up to 80% lifetime prevalence).

ICHD-3 Diagnostic Criteria:

  1. At least 10 episodes lasting 30 min to 7 days
  2. At least 2 of: Bilateral / Pressing or tightening (non-pulsating) / Mild-moderate intensity / NOT aggravated by routine activity
  3. BOTH: No nausea/vomiting AND No more than one of photophobia/phonophobia
  4. Not better accounted for by another ICHD-3 diagnosis

ICHD-3 Subtypes:

  • 2.1 - Infrequent episodic (<1 day/month)
  • 2.2 - Frequent episodic (1-14 days/month)
  • 2.3 - Chronic tension-type headache (≥15 days/month for >3 months)

C. TRIGEMINAL AUTONOMIC CEPHALALGIAS - TACs (ICHD-3 Code: 3)

Cluster Headache (3.1):

  • 4x more common in males - the most severe primary headache
  • Duration: 15-180 minutes per attack
  • Character: Severe/very severe, unilateral orbital/supraorbital/temporal, stabbing/boring ("hot poker behind the eye")
  • Autonomic features (ipsilateral): lacrimation, conjunctival injection, nasal congestion/rhinorrhoea, ptosis, miosis (partial Horner's), facial sweating
  • Restlessness - patients pace during attack (opposite of migraine - lie still)
  • Periodicity: 1-8 attacks/day during cluster periods of weeks-months, then pain-free intervals
  • Functional neuroimaging shows posterior hypothalamic activation during attacks
  • Neuroanatomy through Clinical Cases, 3rd Ed.

Other TACs:

  • 3.2 - Paroxysmal hemicrania (more frequent, shorter, responds exclusively to indomethacin)
  • 3.3 - SUNCT (Short-lasting Unilateral Neuralgiform headache with Conjunctival injection and Tearing)
  • 3.4 - SUNA (Short-lasting Unilateral Neuralgiform headache with cranial Autonomic symptoms)
  • 3.5 - Hemicrania continua (continuous, unilateral, indomethacin-responsive)

D. OTHER PRIMARY HEADACHES (ICHD-3 Code: 4)

  • 4.1 - Primary cough headache (onset with Valsalva)
  • 4.2 - Primary exercise headache
  • 4.3 - Primary headache associated with sexual activity ("thunderclap" at orgasm)
  • 4.4 - Primary thunderclap headache (must always rule out subarachnoid hemorrhage)
  • 4.7 - Primary stabbing headache ("ice-pick headache")
  • 4.8 - Nummular headache (coin-shaped area of scalp)
  • 4.10 - New daily persistent headache (NDPH)

PART 4 - SECONDARY HEADACHES (ICHD-3 Parts 5-12)

Secondary headache is caused by an underlying disorder. Always investigate when RED FLAGS are present.

Key Secondary Causes (Organized by the Neurologic Arrowhead):

CategoryExamples
VascularSubarachnoid hemorrhage, CVST, carotid dissection, reversible cerebral vasoconstriction syndrome (RCVS)
Infectious/InflammatoryMeningitis, encephalitis, COVID-19, vasculitis
Structural/PressureBrain tumor, hydrocephalus, idiopathic intracranial hypertension (IIH), low CSF pressure
TraumaPost-traumatic headache (ICHD-3 code 5)
SubstanceMedication overuse headache (MOH), alcohol, CO poisoning
MetabolicHypertension, hypoxia, dialysis
Cranial structuresSinusitis, glaucoma, cervicogenic, dental, TMJ

ICHD-3: Medication Overuse Headache (MOH) - Code 8.2

A critically important secondary type:
  • Headache on ≥15 days/month in a patient taking acute pain medications on ≥10-15 days/month for >3 months
  • The most preventable cause of chronic daily headache
  • All acute headache drugs can cause MOH (triptans, NSAIDs, opioids, combination analgesics)

PART 5 - RED FLAG SYMPTOMS ("SNOOPIEST" Mnemonic)

These require urgent imaging and investigation to rule out dangerous secondary causes:
Red FlagConcern
Systemic symptoms (fever, weight loss)Meningitis, malignancy
Neurological deficitsStroke, mass lesion
Onset - sudden/thunderclap ("worst headache of life")Subarachnoid hemorrhage
Older age (new headache >50 yr)Giant cell arteritis, malignancy
Progressive worseningMass lesion, hydrocephalus
Immune compromise (HIV, steroids)Opportunistic infection
Endocrine (pregnancy, postpartum)CVT, PRES
Signs of raised ICP (wakes from sleep, worse with Valsalva)Hydrocephalus, tumor
TraumaEpidural/subdural hematoma

PART 6 - TREATMENT (Evidence-Based)

Acute Treatment of Migraine

The landmark BMJ network meta-analysis 2024 (PMID: 39293828) - 137 RCTs, 89,445 participants - ranked all oral acute migraine drugs:
Top-ranked drugs for pain freedom at 2 hours:
  1. Eletriptan - most effective (OR 5.19 vs placebo)
  2. Rizatriptan (OR 4.43)
  3. Sumatriptan (OR 3.79)
  4. Zolmitriptan (OR 3.30)
  5. Newer agents: Lasmiditan (ditan), Rimegepant/Ubrogepant (gepants/CGRP antagonists) - effective but less so than top triptans
Key conclusion: Eletriptan, rizatriptan, sumatriptan, and zolmitriptan should be considered preferred first-line acute treatment and included in the WHO Essential Medicines List.
Step-care approach:
  1. Mild attacks: NSAIDs (ibuprofen, naproxen), paracetamol, aspirin ± antiemetics (metoclopramide)
  2. Moderate-severe attacks: Triptans (5HT1B/D agonists) - sumatriptan SC/nasal most rapid
  3. Cardiovascular contraindications to triptans: Gepants (rimegepant, ubrogepant) or lasmiditan
  4. Nausea/vomiting: IV/IM antiemetics (prochlorperazine, chlorpromazine, metoclopramide)
  5. Status migrainosus: IV valproate, IV dexamethasone, IV dihydroergotamine

Preventive Treatment of Migraine

Indicated when: ≥4 headache days/month, significant disability (MIDAS score), MOH risk, or patient preference.
The 2025 IHS Evidence-Based Guidelines (Cephalalgia, PMID: 40277321) and the 2026 Lancet Neurology review (PMID: 41722594) both endorse:
Tier 1 - Migraine-Specific (CGRP pathway):
  • Anti-CGRP monoclonal antibodies (injectable, monthly/quarterly): Erenumab (Aimovig), Fremanezumab (Ajovy), Galcanezumab (Emgality), Eptinezumab (IV)
  • Reduce monthly migraine days by 50% in ~50% of patients
  • Superior adherence vs. traditional preventives
  • Work in patients who failed other preventives
Tier 2 - Traditional Preventives:
  • Beta-blockers: Propranolol, metoprolol (first-line, Level A evidence)
  • Anticonvulsants: Topiramate, valproate
  • Antidepressants: Amitriptyline (especially with comorbid tension-type or insomnia)
  • Calcium channel blockers: Flunarizine (not available in US), verapamil
  • NSAIDs: Naproxen (for menstrual migraine)
  • Nutraceuticals: Magnesium (400-600 mg/day), Riboflavin/B2 (400 mg/day), Coenzyme Q10, Butterbur (PA-free)
Botulinum toxin A (OnabotulinumtoxinA/Botox): FDA-approved for chronic migraine (≥15 days/month). 155-195 units IM across 31-39 sites every 12 weeks.

Cluster Headache Treatment

Acute:
  • Inhaled 100% O2 (12-15 L/min for 15 min) - aborts ~70% of attacks, safest option
  • Subcutaneous sumatriptan (6 mg) - most effective abortive
  • Intranasal zolmitriptan
Preventive:
  • Verapamil (240-960 mg/day) - first-line, titrate carefully with ECG monitoring
  • Lithium - for chronic cluster headache
  • Galcanezumab - now approved for episodic cluster headache
  • Short-term: Prednisolone taper, suboccipital steroid injections

Tension-Type Headache Treatment

Acute: Simple analgesics (ibuprofen, paracetamol, aspirin). Avoid opioids.
Preventive: Amitriptyline (10-75 mg at night) is first-line. Mirtazapine as alternative. Stress management, physiotherapy, biofeedback.

PART 7 - EPIDEMIOLOGY & GLOBAL BURDEN

  • Headache affects ~52% of the global population (IHS data)
  • Migraine is the 2nd leading cause of years lived with disability (YLD) worldwide (GBD 2019)
  • Tension-type headache is most prevalent but migraine causes most disability
  • Migraine is underdiagnosed and undertreated globally - only 2 in 5 sufferers are ever diagnosed
  • Headache costs the EU economy an estimated €111 billion/year in lost productivity

PART 8 - ICHD-4 (IN PROGRESS, 2025-2026)

The IHS Classification Committee under Prof. Peter J. Goadsby is currently developing ICHD-4. Published as "Work in Progress 1" in Cephalalgia (2024, IHS classification page). ICHD-IV workshops were held in September 2025. The new edition will refine criteria based on field testing, genetics, biomarker research, and neuroimaging findings accumulated since 2018.

Key Reference Summary

SourceDetails
ICHD-3 (2018)ichd-3.org - Gold standard classification, Cephalalgia 38:1-211
ICHD HistoryOlesen J. Cephalalgia 2024 - PMID 38166472
Acute migraine treatmentKarlsson WK et al. BMJ 2024 - PMID 39293828
IHS Pharmacological GuidelinesOrnello R et al. Cephalalgia 2025 - PMID 40277321
Migraine prevention (CGRP)Martinelli D et al. Lancet Neurol 2026 - PMID 41722594
Pediatric migraine guidelinesHassan A et al. Cephalalgia 2026 - PMID 41699419
Migraine vs TTH debateOnan D et al. J Headache Pain 2023 - PMID 37474899
Neuroanatomy textbookNeuroanatomy through Clinical Cases, 3rd Ed., pp. 164-166
This is a shared conversation. Sign in to Orris to start your own chat.